Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck has initiated talks with the Indian health ministry to supply Gardasil vaccines for use in government health institutions. Merck has launched the human papillomavirus vaccine Gardasil in India at half its international price and intends to make the drug available to a larger population base through the government's national immunization programs (PharmAsia News, Oct. 14, 2008)
You may also be interested in...
India’s Supreme Court To Govt: Respond To Charges Of Safety Breech In Gardasil, Cervarix
In the latest of a series of court interventions, the Supreme Court has asked the regulatory agency to come clear on approvals for Gardasil and Cervarix.
Merck Launches Gardasil In India At Half U.S. Price
MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350
New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup
PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1